Harbour BioMed’s AI-Enabled Obesity Antibody LET003 Has IND Accepted

What happened
On November 18, 2026, Harbour BioMed announced that China's National Medical Products Administration accepted its investigational new drug application for LET003. LET003 is a monoclonal antibody developed using the company's Hu-mAtrIx AI platform and is designed to treat overweight or obesity by blocking the ACVR2A and ACVR2B receptors. The acceptance allows LET003 to move into clinical development, though all efficacy data so far come from preclinical studies. The drug is part of Harbour BioMed’s global obesity program.
Key details
- LET003 is Harbour BioMed's first drug candidate created with the Hu-mAtrIx AI platform.
- The antibody targets ACVR2A and ACVR2B receptors to address obesity.
- Preclinical studies showed LET003 combined with semaglutide enhanced fat reduction and preserved lean mass.
- LET003 showed lean-mass-promoting effects at a lower dose compared to bimagrumab at a higher dose in preclinical tests.
- The Hu-mAtrIx platform uses a protein large language model trained on 9 million antibody sequences.
Why it matters
Pharmaceutical companies and healthcare providers focused on obesity treatment now have a potential new therapeutic candidate entering clinical trials in China. The acceptance of the IND means LET003 can be tested in humans, which could lead to new options for patients if clinical results confirm preclinical findings. Harbour BioMed’s use of AI in drug design is also being tested for its ability to deliver clinically viable antibody therapies.
